CLINICAL TRIALS PROFILE FOR DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

All Clinical Trials for diphenhydramine hydrochloride; ibuprofen

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00122278 ↗	Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines	Completed	Montefiore Medical Center	Phase 3	2005-07-01	Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo.
NCT00129506 ↗	Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion	Completed	Ibis Reproductive Health	Phase 4	2005-05-01	Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
NCT00129506 ↗	Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion	Completed	Wiebe, Ellen, M.D.	Phase 4	2005-05-01	Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
NCT01014767 ↗	Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors	Terminated	Tufts Medical Center	Phase 3	2009-11-01	This is a "tissue banking and data review" research study that also has a "clinical" research part: - The goal of the tissue banking part of this study is to store tissue in a research tissue bank by the International Society for Pediatric Oncology (SIOP) at an international reference center for choroid plexus tumors. The tissue will be used in future research related to cancer. - The goal of the data review part of this study is to collect information from the medical records of patients with choroid plexus tumors, and to store the information in SIOP databases for use in future research related to cancer. - The goal of this clinical research study is to compare 4 chemotherapy treatments for choroid plexus tumors. The safety and level of effectiveness of these study treatments will be compared and studied. The study drugs include different combinations of etoposide, carboplatin, vincristine, cyclophosphamide, methotrexate, doxorubicin, cisplatin, dactinomycin, temozolomide, and irinotecan.
NCT01053208 ↗	Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fasting Condition	Completed	Dr. Reddy's Laboratories Limited	Phase 1	2008-04-01	To determine the single-dose oral bioequivalence study of Ibuprofen and Diphenhydramine citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories Limited, India and Advil® PM, of Wyeth consumer health care, USA, in normal, healthy, adult, human subjects under fasting conditions.
NCT01053338 ↗	Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fed Condition	Completed	Dr. Reddy's Laboratories Limited	Phase 1	2008-04-01	To determine the single-dose oral bioequivalence study of Ibuprofen and Diphenhydramine citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories Limited, India and Advil®PM, of Wyeth consumer health care, USA, in normal, healthy, adult, human subjects under fed conditions.
NCT01118273 ↗	Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine	Completed	Bayer	Phase 4	2008-01-01	The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination

Clinical Trial Conditions for diphenhydramine hydrochloride; ibuprofen

Condition Name

Condition Name for diphenhydramine hydrochloride; ibuprofen
Intervention	Trials
Healthy	2
Pain	2
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive	1
Choroid Plexus Tumors	1

Condition MeSH

Condition MeSH for diphenhydramine hydrochloride; ibuprofen
Intervention	Trials
Migraine Disorders	2
Headache	2
Stomatitis	1
Leukemia	1

Clinical Trial Locations for diphenhydramine hydrochloride; ibuprofen

Trials by Country

Trials by Country for diphenhydramine hydrochloride; ibuprofen
Location	Trials
United States	7
India	2
Germany	1
Canada	1
New Zealand	1

Trials by US State

Trials by US State for diphenhydramine hydrochloride; ibuprofen
Location	Trials
California	1
Oregon	1
Connecticut	1
Utah	1
Texas	1

Clinical Trial Progress for diphenhydramine hydrochloride; ibuprofen

Clinical Trial Phase

Clinical Trial Phase for diphenhydramine hydrochloride; ibuprofen
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for diphenhydramine hydrochloride; ibuprofen
Clinical Trial Phase	Trials
Completed	7
Not yet recruiting	2
Terminated	1

Clinical Trial Sponsors for diphenhydramine hydrochloride; ibuprofen

Sponsor Name

Sponsor Name for diphenhydramine hydrochloride; ibuprofen
Sponsor	Trials
Dr. Reddy's Laboratories Limited	2
Guangzhou Kangqi Medical Technology Co., LTD	1
Tufts Medical Center	1

Sponsor Type

Sponsor Type for diphenhydramine hydrochloride; ibuprofen
Sponsor	Trials
Other	9
Industry	6
NIH	1

Diphenhydramine Hydrochloride and Ibuprofen: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

What is the current clinical-trials posture for diphenhydramine HCl?

Diphenhydramine hydrochloride (DPH) is a first-generation H1 antihistamine marketed in multiple dosage forms (oral tablets/capsules, syrups, topical, and injectable in some jurisdictions). Its clinical footprint is dominated by older evidence, with today’s trial activity concentrated in niche comparisons (formulation, bioequivalence, and specific symptom endpoints such as allergic rhinitis), plus occasional safety/tolerability and pediatric/adolescent studies.

Clinical-trials activity profile (directional)

• Trial types: formulation/bioequivalence, symptom response comparisons, sedative-effect and safety characterization, and specific indications such as allergic rhinitis or pruritus.
• Geographic spread: typically US, EU, and Asia-Pacific sites depending on the sponsor and dosage form.
• Enrollment scale: commonly small-to-midsize studies rather than global Phase 3 efficacy programs.

Implication for R&D

• New development is more frequently positioned around line extensions (dose/formulation), competitive differentiation (time-to-onset, taste/mask, pediatric suitability), and label refinements than around novel MoA efficacy breakthroughs.

What is the current clinical-trials posture for ibuprofen?

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) with extensive global use across analgesic and anti-inflammatory indications. Contemporary trial activity is also skewed toward:

• Formulation and dosing (rapid-release vs extended-release, pediatric formulations, solubility-enhanced products),
• Comparative efficacy and safety within the NSAID class,
• Special populations (pediatrics, geriatrics, GI-risk stratified groups).

Clinical-trials activity profile (directional)

• Trial types: comparative pain/inflammation outcomes, pharmacokinetics (PK), and gastrointestinal tolerability measures.
• Dose regimens: standardized by existing label dose ranges; differentiation tends to come from onset and tolerability.
• Study endpoints: pain scores, functional outcomes, rescue medication use, and adverse event profiles, especially GI and cardiovascular risk signals.

Implication for R&D

• The competitive advantage in ibuprofen development usually comes from pharmaceutical performance (onset, consistency, bioavailability) and risk mitigation (buffered/solubility approaches, patient selection, and co-formulation strategies).

Where does the market sit for each product today?

DPH and ibuprofen participate in distinct consumer and professional channels, but both operate in highly mature, price-competitive segments with strong generic penetration.

Diphenhydramine HCl market: demand drivers and economics

Primary demand drivers

• Seasonal and year-round allergy symptom control (where DPH remains indicated in local markets).
• Sleep/OTC use for antihistamine-related drowsiness (regulatory status varies by jurisdiction and label).
• Motion-sickness and symptomatic itch/pruritus uses in certain countries and formulations.

Competitive structure

• Extensive generic supply.
• Differentiation usually comes from formulation (liquid, chewable, topical), packaging, and brand trust rather than new clinical benefit.

Key pricing dynamics

• OTC price compression is common where generics are dominant.
• Value capture concentrates in pharmacy distribution efficiency and brand-level loyalty where branded SKUs still exist.

Ibuprofen market: demand drivers and economics

Primary demand drivers

• OTC and prescription use across pain (headache, musculoskeletal pain), fever, and inflammation.
• Pediatric and adult self-medication demand.
• Large institutional use in acute and outpatient settings where NSAIDs are first-line for many pain syndromes.

Competitive structure

• Very high generic penetration in most major markets.
• Differentiation concentrates on:
  • pediatric suspensions and dosing devices,
  • rapid onset formulations,
  • combination products in certain jurisdictions (subject to local regulatory frameworks).

Key pricing dynamics

• Strong downward pressure from generics and retailer private label.
• Product performance and patient adherence can influence share more than clinical claims.

What is the likely forward market outlook and growth shape?

Both drugs likely follow a mature-market trajectory: low double-digit topline growth is uncommon; volume and share gains tend to come from incremental formulation conversions, packaging innovation, and channel execution.

Diphenhydramine HCl: projection logic

Base case growth levers

• Higher turnover in OTC allergy cycles (seasonal peaks).
• Expansion of pediatric-friendly dosage forms (where regulatory approvals support it).
• Repositioning within itch and allergy symptom management in select markets.

Constraints

• Safety and tolerability scrutiny around sedation and anticholinergic effects, especially in older populations.
• Risk of tighter label restrictions in some jurisdictions for certain uses.

Projection shape (directional)

• Moderate volume stability with periodic share shifts based on formulation availability and seasonal demand.

Ibuprofen: projection logic

Base case growth levers

• Continued OTC penetration and ongoing pediatric usage cycles.
• Adoption of faster onset or more palatable pediatric formulations.
• Institutional buy-side stability due to predictable safety at labeled doses.

Constraints

• Long-standing safety discourse around GI and cardiovascular risks for chronic or high-dose use.
• Ongoing substitution by other analgesic/anti-inflammatory agents depending on payer and formulary preferences.

Projection shape (directional)

• Mature demand with incremental growth where formulation improvements and channel execution outpace price decline.

How do clinical development and market strategy intersect for these two actives?

A practical pattern emerges for both DP H and ibuprofen: the “clinical” work that matters commercially is often the work that de-risks manufacturing equivalence and confirms patient-relevant performance.

Diphenhydramine HCl: where trials translate into sales

• Bioequivalence and formulation performance claims support generic entry and line extensions.
• Symptom endpoint studies support label wording (in-market) and formulary acceptance.
• Sedation/safety assessments influence OTC positioning and retailer eligibility.

Ibuprofen: where trials translate into sales

• PK and pain-onset studies support rapid-release differentiation.
• Pediatric palatability and dosing accuracy studies reduce adherence drop-off and support shelf-space.
• GI tolerability comparisons influence access in sensitive patient segments.

What market projection should investors and R&D teams use?

Use a two-track model: (1) volume-led execution and (2) margin-led SKU strategy.

Diphenhydramine HCl

• Volume-led execution: seasonal allergy season capture, pediatric and topical expansion.
• Margin-led SKU strategy: focus on differentiated dosage forms that reduce substitution and support higher net pricing.

Ibuprofen

• Volume-led execution: strong channel turnover through OTC and pediatric cycles.
• Margin-led SKU strategy: faster onset and better palatability formulations where performance claims are supported by clinical data and regulatory pathways.

Actionable commercialization takeaways

• For both actives, the highest-probability development path is formulation and performance work rather than novel efficacy paradigms.
• Commercial differentiation should map to endpoints that regulators and wholesalers care about: PK, onsets, tolerability, and pediatric usability.
• Pricing will remain constrained by generic competition; therefore, share gains depend on pack architecture, pharmacy placement, and medical-channel reliability.

---

Key Takeaways

• Diphenhydramine HCl and ibuprofen are mature, highly genericized actives where trial activity centers on formulation, performance, and symptom endpoint comparisons rather than new MoA breakthroughs.
• Clinical programs with the strongest commercial impact focus on bioequivalence, onset, tolerability, and patient usability (especially pediatrics for ibuprofen and palatability/sedation profiling for diphenhydramine).
• Market outlook is mature-market: growth comes from incremental conversion to improved dosage forms and channel execution, not from broad efficacy expansion.
• Investment and R&D prioritization should favor development that reduces regulatory and competitive friction while protecting net pricing through differentiated SKU design.

FAQs

1) Are there meaningful late-stage efficacy trials for either diphenhydramine HCl or ibuprofen today?

Late-stage efficacy trials are uncommon relative to formulation and comparative studies. The dominant trial mix is performance and patient-relevant endpoint work aligned with incremental label and product positioning.

2) Where do formulation studies matter most for these drugs?

For diphenhydramine HCl, formulation studies matter for sedation-related usability and topical/oral performance. For ibuprofen, they matter for onset, pediatric palatability, and tolerability outcomes.

3) What endpoints typically drive regulatory acceptance in these development programs?

Commonly used endpoints include PK/BE metrics, symptom response scores aligned to labeling, pain/fever measures, and adverse event profiles focusing on tolerability.

4) How do generic dynamics affect market projection?

Generic penetration compresses prices and limits revenue growth to volume, mix, and differentiated SKU strategies where those strategies can maintain net price.

5) What is the most investable growth lever for these mature actives?

Differentiated formulation and delivery systems that improve patient usability and performance while enabling fast, low-friction regulatory pathways.

---

References

[1] U.S. Food and Drug Administration. Drug Approval Reports and Labeling Resources (accessed 2026-04-28).
[2] EMA. European Public Assessment Reports (EPAR) and product information for ibuprofen and antihistamine products (accessed 2026-04-28).
[3] ClinicalTrials.gov. Diphenhydramine hydrochloride and ibuprofen trial records and status listings (accessed 2026-04-28).